NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy
LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR)...
Brain
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE)...
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025...
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to...
Omni-Biotic US Expands Into Children’s Gut Health With Two New Probiotics: AB 10 Kids and Stress Release Kids
NEW YORK CITY, NEW YORK / ACCESS Newswire / September 17, 2025 / Omni-Biotic US, the company that introduced Europe's...
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational...
AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical...
CervoMed Highlights Neflamapimod’s Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apneaNEW...
Hemostemix to Present at Life Science Investor Forum
Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Optigenex Inc. Reports Positive Results in a Group of Human Subjects with Normal Cognitive Function, in a Double-Blind, Cross Over, Placebo Controlled, Randomized Cognitive Study with ac-11(R)
Study Sponsored by Optigenex Inc. and conducted by the University of Northern Arizona led by Doctor Oneil Guthrie, demonstrates significant...
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Arterial HealthTech CONNEQT Declares the Future of Heart Health Has Arrived
NAPERVILLE, Ill., Sept. 16, 2025 /PRNewswire/ -- Apple Watch just delivered the alert. The Pulse from CONNEQT Health delivers the answer....
Trinity Capital Inc. Provides Up to $50 Million in Growth Funding to Nalu Medical, Supporting Continued Commercial Momentum
PHOENIX, Sept. 16, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the...
Sharps Technology and BONK Announce Staking Collaboration, Bridging Institutional Capital and Web3 Culture
NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Sharps Technology ("Sharps Technology" or the "Company") (NASDAQ: STSS), a medical device company...
BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...
BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...
Israeli Med-Tech Delegation Builds Bridges in Romania’s Healthcare System
BUCHAREST, Romania, Sept. 16, 2025 /PRNewswire/ -- Bucharest hosted an important visit this week, as IMPROVATE organized a high-level Israeli medical technology...
Moberg Analytics Launches AI Platform for Brain-Injured Patients
PHILADELPHIA, Sept. 15, 2025 /PRNewswire/ -- Moberg Analytics today announced the launch of its flagship Moberg Clinical Platform (MCP), the...
CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million
This release contains a headline correction from the previous publication.Positive start to FY 2026 with steady revenue, data growth and...